PARP1 and neoplasm: Given the increased T cell inflammation in HRD positive tumors as well as preclinical studies showing the synergistic anti-tumor effects of PARP inhibitors and CTLA or PD(L)1 blockade in EOC carrying BRCA mutations (17) several trials exploring the same combination are ongoing in BRCA mutated and BRCA wild-type patients, respectively (NCT02571725; NCT02485990; NCT02953457).